Artificial Intelligence in Oncology Market Size and Share - Growth Analysis Report and Forecast Trends (2026-2035)

The global artificial intelligence in oncology market was valued at USD 3.23 Billion in 2025. It is poised to grow at a CAGR of 28.60% during the forecast period of 2026-2035, and reach USD 39.96 Billion by 2035. The market growth is driven by the rising cancer burden, growing adoption of precision medicine, and advancements in AI technologies.

Key Market Trends and Insights

• Based on offerings, the hardware segment led the market with the largest revenue share of above 39% during the historical period.
• Based on cancer type, the breast cancer segment dominated the market, accounting for more than 20% revenue share during the historical period.
• North America held the dominant position in the market, capturing approximately 45% of the total revenue during the historical period.

Market Size and Forecast

• Market Size (2025): USD 3.23 Billion
• Projected Market Size (2035): USD 39.96 Billion
• CAGR (2026-2035): 28.60%

Q1 2026 Market Updates

Overview: For companies and buyers tracking the Artificial Intelligence In Oncology sector, Q1 2026 was a quarter unlike any recent precedent. Demand signals for the global artificial intelligence in oncology market through healthcare system stress-testing, defense medical digitalization, and the validation of remote care and AI-enabled health technology under conflict-proximate conditions. Conflict-driven healthcare system overload, with Israeli hospitals managing exceptional casualty volumes and Gulf state healthcare systems maintaining continuity during regional uncertainty, proved out the operational importance of digital health platforms, AI clinical decision support, and remote patient monitoring technology. Shield AI's defense AI validation (Shield AI reaching a $12.7 billion valuation (CNBC, March 28, 2026)) and Palantir Maven's deployment (Palantir Maven AI deployed by US and allied forces (Alex Karp, CNBC, March 28, 2026)) reinforce the broader AI technology investment environment that is accelerating AI adoption in healthcare settings.

United States: Looking at the US specifically, Looking at the US market specifically, US artificial intelligence in oncology market demand over Q1 2026 was elevated by defense healthcare digitalization, with military medical facilities adopting advanced clinical IT, AI decision support, and telemedicine platforms to manage elevated caseload from Q1 2026 military operations. US hospital systems invested in cyber security hardening for health IT infrastructure, with Q1 2026 conflict-adjacent cyber threat environment motivating healthcare cyber security investment acceleration. US healthcare AI investment, with companies like Tempus, Veracyte, and emerging AI health startups attracting elevated funding, was reinforced by Q1 2026's validation of AI-enabled decision-making in high-pressure environments. CMS reimbursement expansion for digital health services maintained commercial adoption momentum independent of Q1 2026 disruption.

Iran & Israel: Israel's digital health sector, one of the world's most advanced per-capita medtech ecosystems, demonstrated operational resilience throughout Q1 2026, with health IT systems, telemedicine platforms, and AI diagnostic tools maintaining functionality under conflict-proximate conditions. Israeli digital health companies, including Zebra Medical Vision, MedAware, and dozens of AI diagnostics startups, continued operations and attracted investor attention as conflict proved out the operational value of AI-enabled clinical tools. Gulf state digital health investment, Vision 2030 healthcare digitalization and UAE's Smart Dubai health platform programs, maintained procurement of artificial intelligence in oncology market platforms supported by elevated oil revenues from Brent crude at USD 126/barrel (Wikipedia). Iran's healthcare IT infrastructure, already severely constrained by international software and technology sanctions, faced additional Q1 2026 disruption to digital health capability maintenance.

Key Takeaways

Government & Policy Watch

• Defense healthcare IT: US military medical facility digital health investment is elevated by Q1 2026 operational demands, with AI clinical decision support, telemedicine, and healthcare cyber security receiving accelerated procurement authorization.
• Cyber security investment: Q1 2026 elevated cyber threat environment is accelerating healthcare IT security investment, with hospital systems hardening EHR, medical device, and health analytics infrastructure against state-sponsored cyber attack.
• AI validation: Q1 2026 AI system validation at scale, Shield AI's $12.7B valuation and Palantir Maven deployment, reinforces healthcare investor confidence in AI platform investment across clinical decision support and diagnostics applications.

Market & Industry Impact

• Market growth: The artificial intelligence in oncology market is growing on AI adoption, cloud migration, interoperability mandates, remote care expansion, and value-based care data requirements, with Q1 2026 providing near-term defense healthcare IT demand acceleration.
• AI in clinical care: AI-enabled clinical decision support, medical imaging analysis, and predictive patient monitoring are one of the faster-growing artificial intelligence in oncology market segments, with large language model integration creating new capability dimensions.
• Telehealth permanence: Post-pandemic telehealth permanence, reinforced by Q1 2026 remote care operational validation, continues to drive digital health platform investment across outpatient, chronic care, and mental health service delivery.

Procurement & Supply Chain Alert

• Cyber security risk: Healthcare IT systems represent high-value cyber attack targets, with Q1 2026 conflict-adjacent state-sponsored cyber threat environment creating elevated ransomware, data breach, and system disruption risk for health IT operators.
• Interoperability complexity: Artificial intelligence in oncology market system integration with legacy EHR, medical device, and administrative systems requires extensive API development and data standardization investment, a technical barrier that constrains rapid deployment.
• Regulatory compliance: Digital health products face FDA Software as a Medical Device (SaMD) regulation, HIPAA privacy requirements, and ONC interoperability rules, a multi-framework compliance environment that adds cost and timeline to product development.

Artificial Intelligence in Oncology Market Overview

Artificial Intelligence (AI) is transforming oncology by enhancing early detection, diagnosis, and personalized treatment strategies. AI-powered tools analyze medical imaging, genomics, and clinical data to support precise decision-making. Applications such as cancer prognosis prediction enable clinicians to assess disease progression and optimize therapies. Additionally, AI improves drug discovery, treatment planning, and patient monitoring, ultimately increasing efficiency and improving survival outcomes in cancer care. The market reached a value of approximately USD 3.23 Billion in 2025.

Artificial Intelligence in Oncology Market Growth Drivers

Rising Global Cancer Burden Driving the Market Demand

The global cancer burden continues to rise, with over 50 million people living with cancer, including 7.8 million breast cancer cases and over 2 million lung cancer cases worldwide. This increasing prevalence is driving demand for advanced solutions such as cancer prognosis prediction to improve early detection and personalized treatment. Growing patient volumes and complexity of care are accelerating the adoption of AI technologies across oncology workflows.

Artificial Intelligence in Oncology Market Trends

Key trends shaping the market include increasing integration of AI in oncology workflows, rising adoption of precision medicine, advancements in imaging analytics, and growing use of AI-driven tools for cancer prognosis prediction and clinical decision support.

Strategic Acquisitions Accelerating AI Integration in Oncology

Rising cancer prevalence and growing demand for precision medicine are driving adoption of cancer prognosis prediction and AI-powered oncology solutions globally. In January 2026, AstraZeneca announced the acquisition of Modella AI to strengthen its capabilities in oncology drug discovery and clinical development. This move reflects a growing trend of pharmaceutical companies integrating advanced AI models into biomarker identification and clinical trial optimization. Such investments highlight the role of drug response prediction in enhancing research efficiency and accelerating innovation.

Artificial Intelligence in Oncology Market Segmentation

Market Breakup by Offerings

• Software
• Hardware
• Services

Market Breakup by Technology

• Machine Learning
• Natural Language Processing
• Context-Aware Processing and Computing
• Computer Vision
• Imaging Analysis
• Others

Market Breakup by Application

• Drug Discovery and Development
• Diagnosis and Early Detection
• Treatment Planning and Personalization
• Patient Engagement and Remote Monitoring
• Post-Treatment Surveillance and Care
• Data Management and Analytics
• Others

Market Breakup by Cancer Type

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Brain Cancer
• Leukemia
• Lymphoma
• Others

Market Breakup by End User

• Hospitals
• Oncology Clinics
• Academic and Research Institutes
• Medical Device Companies
• Others

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Artificial Intelligence in Oncology Market Share

Breast Cancer to Dominate the Market Segment by Cancer Type

Based on cancer type, the breast cancer segment dominated the market, accounting for more than 20% revenue share during the historical period. This growth is driven by rising screening programs and increasing adoption of AI tools for early detection and diagnosis. Advanced applications such as radiomics are enhancing imaging analysis, enabling precise tumor characterization and improving clinical decision-making, thereby strengthening the segment’s leading position in the global market.

Global Artificial Intelligence in Oncology Market Analysis by Region

North America held the dominant position in the market, capturing approximately 45% of the total revenue during the historical period. The region benefits from strong healthcare infrastructure, significant investments, and early adoption of advanced technologies. Increasing deployment of AI-powered platforms, including tumor board AI, is improving multidisciplinary decision-making and treatment outcomes, further supporting regional leadership and accelerating innovation in oncology care delivery systems.

Leading Players in the Artificial Intelligence in Oncology Market

The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis and strategic initiatives by the leading players. The major companies in the market are as follows:

Aidoc

Aidoc, a global leader in clinical artificial intelligence, has strengthened its role in the market through its expanded partnership with Integral Diagnostics (IDX) in Australia and New Zealand. Leveraging its aiOS™ platform, Aidoc enhances radiologists’ workflows by detecting critical pathologies such as lung nodules, aiding early cancer diagnosis. Its AI integration supports the upcoming National Lung Cancer Screening Program, reinforcing Aidoc's commitment to advancing oncology care through AI-driven medical imaging solutions.

iCAD, Inc.

iCAD, Inc. is a leading medical technology company specializing in Artificial Intelligence solutions for cancer detection and risk assessment, with a strong focus on breast oncology. Its ProFound Breast Health Suite, comprising detection, density, and risk tools, leverages AI to identify invasive cancers earlier and more accurately. iCAD's involvement in the artificial intelligence in oncology market emphasizes improving diagnostic efficiency, patient outcomes, and survival rates through clinically proven, AI-powered technologies.

Microsoft Corporation

Microsoft Corporation is significantly advancing artificial intelligence in oncology through its Azure-powered support for CancerCenter.AI. The platform enables rapid digitization and AI analysis of pathology and radiology scans, expediting cancer diagnostics and reducing errors. By integrating imaging tools and remote collaboration capabilities, Microsoft’s technology enhances diagnostic accuracy, supports faster treatment planning, and addresses the global shortage of oncology specialists.

Cancer Center.ai

CancerCenter.ai is a digital platform specializing in artificial intelligence solutions for oncology. It offers web-based tools for pathology and radiology image analysis, leveraging AI algorithms for tasks such as Gleason scoring, metastasis detection, and Ki-67 indexing. Its PathoCam innovation enables cost-effective slide digitization, enhancing diagnostic accuracy and workflow efficiency. The company plays a pivotal role in advancing AI-driven cancer diagnosis globally.

Other key players in the market are Mursla Bio, SkinVision, Kheiron Medical Technologies Limited, Therapixel, Tempus AI, Inc., and Paige AI Inc., among others.

Key Questions Answered in the Artificial Intelligence in Oncology Market

• What was the artificial intelligence in oncology market value in 2025?
• What is the artificial intelligence in oncology market forecast outlook for 2026-2035?
• What major factors aid the demand for artificial intelligence in oncology market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market’s major drivers, opportunities, and restraints?
• What are the major artificial intelligence in oncology market trends?
• Which offering is expected to dominate the market segment?
• Which technology is projected to lead the market segment?
• Which application is likely to lead the market segment?
• Which cancer type is projected to lead the market segment?
• Which end user is likely to dominate the market segment?
• Who are the key players in the artificial intelligence in oncology market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?